Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05940870 · ClinicalTrials.gov registry record
A Prospective Post-marketing Observational Study Assessing the Safety and Efficacy of Nerivio for Migraine Prevention.
A clinical trial, sponsored by Theranica.
- Completed
- Registry status
- 250
- Enrollment target
NCT05940870 is a clinical trial that has completed, run by Theranica. The registered enrollment target is 250 participants.
The verdict
NCT05940870 has completed, sponsored by Theranica.
- COMPLETED
- Registry status
- 250 participants
- Enrollment target
Study Summary
Nerivio is a remote electrical neuromodulation (REN) device that is FDA-cleared for migraine prevention (as well as for acute treatment of migraine), in individuals 12 and older. The study is a post-marketing, observational, prospective, real-world evidence study assessing the safety, efficacy, and health economics outcomes of Nerivio for migraine prevention in a real-world environment. The study population is naïve Nerivio users, aged 12 and up, who were prescribed Nerivio by their healthcare provider for either prevention treatment (for use every other day) or dual-use treatment (for use every other day and upon the onset of a migraine). The study period per participant is six months. During this period, participants will be requested to use Nerivio according to the instructions of their healthcare provider and to fill out a short daily questionnaire in the Nerivio application
Interventions
- DEVICE Nerivio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2023-07-03 |
| Est. Completion | 2024-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05940870
The ClinicalTrials.gov registry entry for NCT05940870 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theranica, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nerivio is the first listed.
NCT05940870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05940870 about?
NCT05940870 is a clinical study titled "A Prospective Post-marketing Observational Study Assessing the Safety and Efficacy of Nerivio for Migraine Prevention.". Nerivio is a remote electrical neuromodulation (REN) device that is FDA-cleared for migraine prevention (as well as for acute treatment of migraine), in individuals 12 and older. The study is a post-marketing, observational, prospective, real-world evidence study assessing the safety, efficacy, and ...
What is the current status of trial NCT05940870?
This trial is currently completed. The enrollment target is 250 participants. The study started on 2023-07-03. Estimated completion is 2024-08-01.
What interventions are being tested in trial NCT05940870?
The interventions under investigation include: Nerivio (DEVICE).
Who is sponsoring clinical trial NCT05940870?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.